<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04262115</url>
  </required_header>
  <id_info>
    <org_study_id>19-2676</org_study_id>
    <nct_id>NCT04262115</nct_id>
  </id_info>
  <brief_title>Morning Versus Evening Exercise for Adults With Overweight and Obesity</brief_title>
  <acronym>TIC-TOC</acronym>
  <official_title>Feasibility and Acceptability of Morning Versus Evening Exercise for Adults With Overweight and Obesity: A Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to determine the feasibility and acceptability of&#xD;
      randomizing adults with overweight and obesity to an exercise intervention of either&#xD;
      prescribed morning aerobic exercise (AM-EX) or prescribed evening aerobic exercise (PM-EX)&#xD;
      progressing to 2000 kcal/wk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this pilot study is to determine the feasibility and acceptability of&#xD;
      randomizing adults with overweight and obesity to an exercise intervention of either&#xD;
      prescribed morning aerobic exercise (AM-EX) or prescribed evening aerobic exercise (PM-EX)&#xD;
      progressing to 2000 kcal/wk. Specifically, the purpose of this study is to assess&#xD;
      recruitment, retention, and adherence to the exercise interventions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2020</start_date>
  <completion_date type="Actual">July 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of Recruitment (Number of contacts)</measure>
    <time_frame>End of enrollment (estimated between 6 and 12 months)</time_frame>
    <description>Feasibility of recruitment will be evaluated by the number of people who contact study staff expressing interest in the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of Recruitment (eligibility rate)</measure>
    <time_frame>End of enrollment (estimated between 6 and 12 months)</time_frame>
    <description>Feasibility of recruitment will be evaluated by calculating the number of volunteers who contact study staff to express interest in participation, the eligibility rate (number eligible divided by total volunteers)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of Recruitment (enrollment rate)</measure>
    <time_frame>End of enrollment (estimated between 6 and 12 months)</time_frame>
    <description>Feasibility of recruitment will be evaluated by calculating the enrollment rate (number enrolled divided by the number of total volunteers)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to Exercise Intervention (session attendance)</measure>
    <time_frame>Baseline to 15 weeks (reported at Week 15)</time_frame>
    <description>Adherence will be calculated as (number of sessions attended/number of sessions prescribed)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence to Exercise Intervention (kcal adherence)</measure>
    <time_frame>Baseline to 15 weeks (reported at Week 15)</time_frame>
    <description>Adherence will be calculated as (number of kcals prescribed/ number of kcals of exercise completed)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight Change (kg)</measure>
    <time_frame>Baseline to 15 weeks</time_frame>
    <description>Body weight will be measured at baseline and weeks 4, 8, 12, and 15 using a digital scale accurate to ±0.1 kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity Change (min/d)</measure>
    <time_frame>Baseline to 15 weeks</time_frame>
    <description>Physical activity will be measured using the ActivPAL v4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meal Timing Change (clock time of first meal)</measure>
    <time_frame>Baseline to 15 weeks</time_frame>
    <description>Meal timing will be assessed using digital photography paired with a date and time stamp (time of first meal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meal Timing Change (clock time of last meal)</measure>
    <time_frame>Baseline to 15 weeks</time_frame>
    <description>Meal timing will be assessed using digital photography paired with a date and time stamp (time of last meal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Timing Change (mid-point of sleep)</measure>
    <time_frame>Baseline to 15 weeks</time_frame>
    <description>Mid-point of sleep will be measured using the Actiwatch 2 (starting sleep time + (sleep duration/2))</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>AM-EX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will be prescribed morning aerobic exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PM-EX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will be prescribed evening aerobic exercise.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>AM-EX</intervention_name>
    <description>AM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.</description>
    <arm_group_label>AM-EX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PM-EX</intervention_name>
    <description>PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.</description>
    <arm_group_label>PM-EX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or Male&#xD;
&#xD;
          -  Age 18-55 years&#xD;
&#xD;
          -  Body Mass Index 25-40 kg/m2&#xD;
&#xD;
          -  Physically inactive: defined as self-reporting &lt;150 minutes per week of physical&#xD;
             activity at moderate intensity or greater on a regular basis over the past 3 months.&#xD;
&#xD;
          -  No self-report of acute or chronic disease (cardiovascular disease (CVD), diabetes,&#xD;
             gastrointestinal disorders and orthopedic problems in particular)&#xD;
&#xD;
          -  No plans to relocate within the next 6 months&#xD;
&#xD;
          -  No plans for extended travel (&gt; 1weeks) within the next 6 months&#xD;
&#xD;
          -  No nicotine use&#xD;
&#xD;
          -  Live or work within 30 minutes of the AHWC (exceptions may be made at the discretion&#xD;
             of the Study PI on a case by case basis for highly motivated subjects).&#xD;
&#xD;
          -  Capable and willing to give informed consent, understand exclusion criteria, accept&#xD;
             the randomized group assignment, and complete outcome measures.&#xD;
&#xD;
          -  Own a smartphone and willing to download and use text messaging for meal intake and&#xD;
             other related assessments.&#xD;
&#xD;
          -  Have a primary care physician (or are willing to establish care with a primary care&#xD;
             physician prior to study enrollment) to address medical issues which may arise during&#xD;
             screening or study procedures/interventions.&#xD;
&#xD;
          -  For Females&#xD;
&#xD;
               -  Not currently pregnant or lactating&#xD;
&#xD;
               -  Not pregnant within the past 6 months&#xD;
&#xD;
               -  Not planning to become pregnant in the next 6 months; sexually active women of&#xD;
                  childbearing potential may be enrolled if they have had a tubal ligation or use a&#xD;
                  reliable means of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diastolic blood pressure &gt; 100 mm HG or systolic blood pressure &gt; 160 mm HG.&#xD;
&#xD;
          -  Resting heart rate &gt;100&#xD;
&#xD;
          -  Diabetes (fasting glucose ≥126 mg/dL or Hemoglobin A1C ≥6.5%)&#xD;
&#xD;
          -  Undiagnosed hypo- or hyper-thyroidism (TSH outside of the normal range) or history of&#xD;
             uncontrolled thyroid disorder. History of thyroid disease or current thyroid disease&#xD;
             treated with a stable medication regimen for at least 6 months is acceptable.&#xD;
&#xD;
          -  Hematocrit, white blood cell count or platelets significantly outside the normal&#xD;
             reference range.&#xD;
&#xD;
          -  Triglycerides &gt; 400 mg/dL&#xD;
&#xD;
          -  LDL cholesterol &gt;200 mg/dL&#xD;
&#xD;
          -  Abnormal resting electrocardiogram (ECG): serious arrhythmias, including multifocal&#xD;
             PVC's, frequent PVC's (defined as 10 or more per min), ventricular tachycardia&#xD;
             (defined as runs of 3 or more successive PVC's), or sustained atrial tachyarrhythmia;&#xD;
             2nd or 3rd degree A-V block, QTc interval &gt; 480 msec or other significant conduction&#xD;
             defects.&#xD;
&#xD;
          -  Presence or history of any metabolic or chronic health problems which would affect&#xD;
             appetite, food intake, energy metabolism, or ability to optimally participate in the&#xD;
             exercise component including: CVD, peripheral vascular disease, cerebrovascular&#xD;
             disease, significant cardiac arrhythmias or cardiac valve disease, diabetes,&#xD;
             uncontrolled hyper- or hypothyroidism, uncontrolled hypertension, cancer (within the&#xD;
             last 5 years, except skin cancer or other cancers considered cured with excellent&#xD;
             prognosis), HIV infection, significant gastrointestinal disorders (described below),&#xD;
             significant pulmonary disorders (described below), significant renal, musculoskeletal,&#xD;
             neurologic, hematologic, or psychiatric disease.&#xD;
&#xD;
          -  Significant gastrointestinal disorders including: chronic malabsorptive conditions,&#xD;
             peptic ulcer disease, Crohn's disease, Ulcerative Colitis, chronic diarrhea, or active&#xD;
             gallbladder disease.&#xD;
&#xD;
          -  Significant pulmonary disorders including: chronic obstructive pulmonary disease&#xD;
             (COPD), interstitial lung disease, cystic fibrosis, or uncontrolled asthma.&#xD;
&#xD;
          -  Symptoms suggestive of CVD: chest pain, shortness of breath at rest or with mild&#xD;
             exertion, syncope.&#xD;
&#xD;
          -  Regular use of prescription or over-the-counter medications known to significantly&#xD;
             impact appetite, weight, sleep, or energy metabolism (e.g. appetite suppressants,&#xD;
             lithium, stimulants, anti-psychotics, tricyclic antidepressants)&#xD;
&#xD;
          -  Regular use of systemic steroids (other than Oral Contraceptive Pills).&#xD;
&#xD;
          -  Regular use of obesity pharmacotherapeutic agents within the last 6 months.&#xD;
&#xD;
          -  Previous obesity treatment with surgery or weight loss device, except: (1) liposuction&#xD;
             and/or abdominoplasty if performed &gt; 1 year before screening, (2) lap banding if the&#xD;
             band has been removed &gt; 1 year before screening, (3) intragastric balloon if the&#xD;
             balloon has been removed &gt; 1 year before screening (4) duodenal-jejunal bypass sleeve,&#xD;
             if the sleeve has been removed &gt; 1 year before screening or 5) AspireAssist or other&#xD;
             endoscopically placed weight loss device if the device has been removed &gt; 1 year&#xD;
             before screening.&#xD;
&#xD;
          -  Current alcohol or substance abuse&#xD;
&#xD;
          -  Irregular sleep/wake patterns that may hinder ability to consistently exercise at a&#xD;
             certain time of day (e.g. night shift-work, swing shifts, etc)&#xD;
&#xD;
          -  Currently dieting or planning to alter diet during the exercise intervention&#xD;
&#xD;
          -  Nicotine use (past 6 months)&#xD;
&#xD;
          -  History of clinically diagnosed eating disorders including anorexia nervosa, bulimia,&#xD;
             binge eating disorder. Pattern of response on the QEWP-5 suggestive of possible binge&#xD;
             eating disorder or bulimia will require further assessment by the Study MD to&#xD;
             determine if it is appropriate for the subject to participate in the study.&#xD;
&#xD;
          -  Current severe depression or history of severe depression within the previous year,&#xD;
             based on DSM-IV-TR criteria for Major Depressive Episode. Score &gt; 18 on BDI will&#xD;
             require further assessment by the Study MD to determine if it is appropriate for the&#xD;
             subject to participate in the study.&#xD;
&#xD;
          -  History of other significant psychiatric illness (e.g. psychosis, schizophrenia,&#xD;
             mania, bipolar disorder) which in the opinion of the Study MD would interfere with&#xD;
             ability to adhere to dietary or exercise interventions.&#xD;
&#xD;
          -  Currently participating in or planning to participate in any formal weight loss or&#xD;
             physical activity programs or clinical trials.&#xD;
&#xD;
          -  Weight loss &gt;5% in past 3 months for any reason except post-partum weight loss, weight&#xD;
             gain &gt;% in past 3 months requires assessment by PI to determine reason for weight gain&#xD;
             and if it is appropriate for the subject to participate in the study.&#xD;
&#xD;
          -  Weight loss of &gt;50 lbs in past 3 years for any reason except post-partum weight loss.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>56 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seth A Creasy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado - Anschutz Medical Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exercise</keyword>
  <keyword>physical activity</keyword>
  <keyword>weight loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

